Preoperative carbohydrate antigen 195 (CA195) and CEA serum levels as prognostic factors in patients with colorectal cancer
- PMID: 10079391
Preoperative carbohydrate antigen 195 (CA195) and CEA serum levels as prognostic factors in patients with colorectal cancer
Abstract
We evaluated in 214 patients with primary colorectal cancer the prognostic value of the preoperative serum levels of CEA and CA195. For CEA these levels were above the cutoff of 6 ng/ml in 31.3% of patients, whereas for CA195 they were higher than 12 U/ml in 35.9% of patients. The simultaneous use of both antigens increased the sensitivity to 49%, which was significantly higher than that of CEA (p < 0.001) and CA195 (p < 0.01) taken singly. The mean preoperative CEA levels were significantly (p < 0.001) correlated with Dukes' stage only, while there was a significant correlation between preoperative serum levels of CA195 and Dukes' stage (p < 0.001), grade of differentiation (p < 0.01) and tumor location (p < 0.05). The results indicated that high preoperative serum levels of CEA and CA195 were associated with a shorter overall survival (p < 0.0001). In addition, separate Cox multivariate analysis showed that preoperative CA195 was, after Dukes' stage, the strongest factor to predict overall survival (p < 0.0001).
Similar articles
-
Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer.Eur J Cancer. 1996 Jun;32A(7):1156-61. doi: 10.1016/0959-8049(96)00030-5. Eur J Cancer. 1996. PMID: 8758246
-
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.Anticancer Res. 2000 Nov-Dec;20(6D):5195-8. Anticancer Res. 2000. PMID: 11326694
-
Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer.Int J Cancer. 2002 Oct 20;101(6):545-8. doi: 10.1002/ijc.90009. Int J Cancer. 2002. PMID: 12237895
-
Value of carcinoembryonic antigen in the management of colorectal cancer.Dis Colon Rectum. 1994 Mar;37(3):272-7. doi: 10.1007/BF02048166. Dis Colon Rectum. 1994. PMID: 8137675 Review.
-
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.Eur J Cancer. 2003 Apr;39(6):718-27. doi: 10.1016/s0959-8049(02)00811-0. Eur J Cancer. 2003. PMID: 12651195 Review.
Cited by
-
[Clinical utility of serous tumoural markers].Aten Primaria. 2003;32(4):227-39. doi: 10.1016/s0212-6567(03)79257-9. Aten Primaria. 2003. PMID: 12975087 Free PMC article. Spanish. No abstract available.
-
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.Br J Cancer. 2013 Apr 2;108(6):1316-23. doi: 10.1038/bjc.2013.79. Epub 2013 Feb 28. Br J Cancer. 2013. PMID: 23449351 Free PMC article. Clinical Trial.
-
Microinvasion of liver metastases from colorectal cancer: predictive factors and application for determining clinical target volume.Radiat Oncol. 2015 Jun 4;10:125. doi: 10.1186/s13014-015-0428-2. Radiat Oncol. 2015. PMID: 26040515 Free PMC article.
-
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.Clin Pharmacokinet. 2016 Nov;55(11):1381-1394. doi: 10.1007/s40262-016-0406-3. Clin Pharmacokinet. 2016. PMID: 27312193
-
Translational progress on tumor biomarkers.Thorac Cancer. 2015 Nov;6(6):665-71. doi: 10.1111/1759-7714.12294. Epub 2015 Jul 27. Thorac Cancer. 2015. PMID: 26557902 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical